Genmab — April 2020
-
Citi opens 'positive Catalyst Watch' on Genmab Citi analyst Peter Verdult opened a "positive Catalyst Watch" on Genmab and keeps a Buy rating on the shares. The analyst expects that the recommended Phase II dose for Genmab's bispecific blood cancer asset, epcoritamab, along with a partnership deal, could be delivered by mid-year.
-
Thanks E L. Did you hear anything from the Genmab presentation yesterday at Sun Trust?
-
Solsen hvad mener du genmab skal stige med/lægge i efter en aftale?
-
Vel et par hundrede point gætter jeg. Ikke blot aftalen vil påvirke kursen, men også en validering af Genmabs teknologi og evne til at lave store aftaler vil tælle på den positive side. Men i og med vi står foran dara-sc og Arzerra i RRMS kunne jeg godt forestille mig vi gled pænt over nuværende ATH i år.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind